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Relative versus absolute drug-therapy benefits and safety: Lessons from ARISTOTLE
CR Kumana, BMY Cheung, HF Tse
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
Introduction: ARISTOTLE was a double-blind, double-dummy, randomised clinical trial in patients with atrial 
ﬁbrillation and one other risk factor for stroke, and compared oral anticoagulation with warfarin (targeted to 
achieve an international normalised ratio [INR] of 2.0 to 3.0) versus apixaban (5 mg x 2 daily).1 Whilst apixaban 
conferred significantly greater efficacy (stroke/embolic event prevention) and was safer (less frequent 
bleeding), consideration of these issues in relative terms can be uninformative. To appreciate the overall cost-
effectiveness of such treatments, absolute beneﬁts should be considered.
Methods & Results: As previously described,2 we therefore derived unadjusted estimates of relative risk (RR) and 
number needed to treat (NNT)/year values for prophylaxis with apixaban compared to warfarin for principal 
efﬁcacy and safety endpoints published in ARISTOTLE (Table). 
Discussion & Conclusion: Whilst the favourable RR values pertaining to apixaban for stroke / systemic embolism, 
haemorrhagic stroke, and death seem striking, in absolute terms (NNT/year) the benefits appear less 
impressive. Moreover, treatment with the newer oral anticoagulants is currently much more costly than using 
warfarin, though the long-term impact of embolic events and major bleeds are both ﬁnancially and emotionally 
devastating. Thus, when allocating resources for thromboembolic prophylaxis in patients with atrial ﬁbrillation, 
the meagre absolute number of additional events prevented with apixaban must be weighed against the 
consequential long-term accrued savings as well as those from avoidance of INR monitoring. 
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No. of patients 
(median follow-up)
Pre-speciﬁed endpoint %RR (95% conﬁdence 
interval)
NNT/year (95%  conﬁdence 
interval)
Apixaban - 9120 
Warfarin - 9003 
(1.8 years)
Stroke / systemic embolism 80 (66 to 96) 303 (169 to 1501)
Haemorrhagic stroke 51 (35 to 75) 428 (273 to 987) 
Death from any cause 90 (80 to 100) 238 (119 to ?)
The effects of cigarette smoke on lipopolysaccharide-mediated inflammatory responses in  
airway epithelial cells
WYJ Lai, JCW Mak
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
Introduction: Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease. Cigarette smoke is 
the major cause by stimulating the production of inﬂammatory chemokines, such as interleukin-8 (IL-8) and 
monocyte chemoattractant protein-1 (MCP-1), causing chronic inﬂammation in the airways. However, cigarette 
smoking might induce an immunosuppressive effect upon lung infection by bacteria, such as Pseudomonas 
aeruginosa during acute exacerbation in COPD, leading to bacteria colonisation in the airways and further 
chronic inﬂammation in the airway of COPD.
Methods: Human bronchial epithelial cells (BEAS-2B) were cultured and treated with 2% cigarette smoke 
medium (CSM), 1 μg/mL lipopolysaccharide (LPS) or in combination for 24 hours. Supernatant was collected 
and analysed by enzyme-linked immunosorbent assay for the measurements of IL-8 and MCP-1.
Results: Exposure of BEAS-2B cells to 2% CSM induced a signiﬁcant increase in both IL-8 (n = 3; P < 0.05), and 
MCP-1 (n = 3; P < 0.001) and 1 μg/mL LPS also induced signiﬁcant increase in IL-8 and MCP-1 (n = 3; P < 0.001). 
However, LPS-induced release of IL-8 and MCP-1 was signiﬁcantly suppressed by 2% CSM (n = 3; P < 0.001). 
Conclusion: Our data demonstrated that both cigarette smoke and LPS alone can induce the release of IL-8 and 
MCP-1. However, cigarette smoke has immunosuppressive effect as it reduces LPS-induced IL-8 and MCP-1. This 
immunosuppressive effect of cigarette smoke might be due to the impairment of the immune response of the 
airway epithelial cells, leading to bacteria colonisation in the airways, hence becoming more prone to infection.
36
